ABSTRACT
BACKGROUND Asymptomatic SARS-CoV-2 infections are potential sources for transmission.
OBJECTIVES Here, we aimed to profile pre-symptomatic/asymptomatic SARS-CoV-2 infections in Mexico City, its associated comorbidities and outcomes.
METHODS Prospective observational study of SARS-CoV-2 cases assessed by contact tracing within the National Epidemiological Surveillance System in Mexico City. We classified subjects as cases with and without respiratory and non-respiratory symptoms (RS, NRS, respectively) assessed for SARS-CoV-2 using real time RT-PCR from nasopharyngeal swabs to evaluate clinical characteristics as well as features associated with severe COVID-19.
RESULTS Amongst 80735 cases with confirmed SARS-CoV-2 infection as of July 23th, 2020, we identified 9659 cases without RS (12.0%), 5605 had only NRS (6.9%) and 4054 who were initially asymptomatic (5.1%). Compared to asymptomatic cases, NRS cases and those with RS+NRS had higher rates of severe COVID-19 outcomes including hospitalization, ICU admission, and intubation (p<0.001). Mortality was higher for cases with RS+NRS (HR 7.58, 95%CI 4.56-12.58) or NRS (HR 3.13, 95%CI 1.80-5.45) compared to asymptomatic cases, adjusted for age, sex and comorbidities. Predictors for mortality in asymptomatic SARS-Co-V-2 infections, chronic kidney disease, previous exposure with suspected infection cases and older age were predictors for lethality.
CONCLUSIONS Definition of pre-symptomatic/asymptomatic cases has relevant implications for SARS-CoV-2 infection outcomes. Older age and comorbidity impact on the probability of developing severe complications for cases who were asymptomatic or had only NRS at evaluation and were sent for domiciliary treatment. Extending testing for detection of asymptomatic cases must be considered in Mexico to better understand the impact of the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No approval was required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CONFLICT OF INTERESTS: Nothing to disclose.
FUNDING: This research received no specific funding
Data Availability
All data sources and R code are available for reproducibility of results at https://github.com/oyaxbell/covid_asymptomatic_cdmx.
